Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

BriaCell Therapeutics Corp. (V:BCT)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for BCT within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jan 12, 2021 06:30 ET
BriaCell Announces Presentation at the 2021 Keystone Symposia Conference: Emerging Cell Therapies
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce that the Company will present a...
Read full article
Dec 09, 2020 09:00 ET
BriaCell Presents Clinical Data at the 2020 San Antonio Breast Cancer Symposium®
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce the presentation results of the...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
2.04
--
--
Price to Sales - TTM
--
17.64
12.51
Price to Book - most recent quarter
--
7.99
4.00
Price to Cash Flow per share - TTM
--
34.31
16.26
Price to Free Cash Flow per share - TTM
--
--
27.60
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Dec 31, 20202,7822,176
Dec 15, 2020606506
Nov 30, 20201000
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

BriaCell Therapeutics Corp. is a Canada-based immuno-oncology focused biotechnology company developing targeted approaches for the management of cancer. The Company, in collaboration with Incyte Corporation, is conducting a Phase I/IIa clinical trial of Bria-IMT in combination with Incyte drugs, INCMGA00012 and epacadostat, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and manufacturing logistics associated with other personalized immunotherapies.

See business summary

 

Twitter

Search (past week) for $BCT.CA BCT.V